Australia's most trusted
source of pharma news
Friday, 04 July 2025
Posted 3 July 2025 PM
AstraZeneca CEO Pascal Soriot is reportedly plotting to move the company's primary stock listing from London to the US and is even considering relocating its headquarters stateside too.
The report in the British newspaper, The Times, claims the plan has been confirmed by "multiple sources" though all are unnamed. It said Soriot had referenced a shift from the UK to the US "in private conversations on numerous occasions".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.